Triazine compounds and pharmaceutical use thereof

Patent metadata

Field	Value
Publication number	US-12398111-B2
Application number	US-202217575931-A
Country	US
Kind code	B2
Filing date	Jan 14, 2022
Priority date	Feb 20, 2014
Publication date	Aug 26, 2025
Grant date	Aug 26, 2025

Abstract

Provided is a compound having an mPGES-1 inhibitory activity and useful for the prophylaxis or treatment of pain, rheumatism, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arteriosclerosis, glaucoma, ocular hypertension, ischemic retinal disease, systemic scleroderma and cancer including colorectal cancer.
A compound represented by the formula [I] or a pharmaceutically acceptable salt thereof:

wherein each symbol is as defined in the SPECIFICATION.

First claim

The invention claimed is:

1. A compound represented by the formula [I] or a pharmaceutically acceptable salt thereof:

wherein
X is CH,
ring Cy is
the formula:

wherein R 1 is
(1) halogen,
(2) C 1-6 alkyl,
(3) cyano or
(4) haloC 1-4 alkyl,
R 3 is
(1) halogen,
(2) hydroxy,
(3) C 1-6 alkyl or
(4) —OR c , wherein the R c is C 1-6 alkyl optionally substituted by 1, 2 or 3 substituents selected from the group consisting of the following (a) to (f);
(a) halogen,
(b) hydroxy,
(c) C 1-6 alkoxy,
(d) —C(O)NR c1 R c2 , wherein the R c1 and the R c2 are each independently hydrogen or C 1-6 alkyl,
(e) C 6-10 aryl, wherein the C 6-10 aryl is optionally substituted by 1, 2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C 1-6 alkyl,
(iv) C 1-6 alkoxy, and
(v) haloC 1-4 alkyl, and

(f) 5- or 6-membered heteroaryl containing 1, 2 or 3 nitrogen atoms, oxygen atoms or sulfur atoms, wherein the heteroaryl is optionally substituted by 1, 2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C 1-6 alkyl,
(iv) C 1-6 alkoxy, and
(v) haloC 1-4 alkyl, and
R 4 is
(1) hydrogen,
(2) halogen,
(3) C 1-6 alkyl or
(4) C 1-6 alkoxy,
R 5 is
(1) halogen,
(2) hydroxy,
(3) C 1-6 alkylsulfanyl,
(4) C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted by 1, 2 or 3 substituents selected from the group consisting of halogen, C 6-10 aryl and C 1-6 alkoxy,
(5) C 3-7 cycloalkyl,
(6) —OR d , wherein the R d is
(a) C 2-6 alkynyl,
(b) C 3-7 cycloalkyl optionally substituted by 1, 2 or 3 C 1-6 alkyls or
(c) C 1-8 alkyl, wherein the C 1-8 alkyl is optionally substituted by 1, 2 or 3 substituents selected from the group consisting of the following (i) to (v);
(i) halogen,
(ii) C 6-10 aryl,
(iii) C 1-6 alkoxy,
(iv) C 3-7 cycloalkyl, wherein the C 3-7 cycloalkyl is optionally substituted by 1, 2 or 3 substituents selected from the group consisting of C 1-6 alkyl and haloC 1-4 alkyl, and
(v) 4-, 5- or 6-membered saturated heterocyclyl containing 1, 2 or 3 nitrogen atoms, oxygen atoms or sulfur atoms, wherein the saturated heterocyclyl is optionally substituted by 1, 2 or 3 substituents selected from the group consisting of C 1-6 alkyl and haloC 1-4 alkyl or

(7) the formula:

wherein R e is
(a) C 1-6 alkyl,
(b) C 3-7 cycloalkyl,
(c) 5- or 6-membered heteroaryl containing 1, 2 or 3 nitrogen atoms, oxygen atoms or sulfur atoms, or
(d) C 6-10 aryl, wherein the C 6-10 aryl is optionally substituted by 1, 2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) C 1-6 alkyl,
(iii) haloC 1-4 alkyl,
(iv) C 1-6 alkoxy, and
(v) haloC 1-4 alkoxy, and

m1 is 0, 1, 2 or 3 and, when m1 is 2 or 3, each R 5 is selected independently,
excluding 4,6-bis-(2,5-dimethyl-phenyl)-1,3,5-triazin-2-ol.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is
(1) chloro,
(2) methyl,
(3) cyano or
(4) trifluoromethyl.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 4 is hydrogen.

4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 is
(1) halogen,
(2) hydroxy,
(3) C 1-6 alkyl or
(4) —OR c , wherein the R c is C 1-6 alkyl optionally substituted by 1, 2 or 3 substituents selected from the group consisting of the following (a) to (f)
(a) halogen,
(b) hydroxy,
(c) C 1-6 alkoxy,
(d) —C(O)NR c1 R c2 , wherein the R c1 and the R c2 are each independently hydrogen or C 1-6 alkyl,
(e) phenyl, wherein the phenyl is optionally substituted by 1, 2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C 1-6 alkyl,
(iv) C 1-6 alkoxy, and
(v) haloC 1-4 alkyl, and

(f) pyridyl, wherein the pyridyl is optionally substituted by 1, 2 or 3 substituents selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C 1-6 alkyl,
(iv) C 1-6 alkoxy, and
(v) haloC 1-4 alkyl.

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein m1 is 1, and
R 5 is the formula:

wherein R e is as defined in claim 1 .

6. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. A method of inhibiting mPGES-1, comprising administering a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof to a human in need thereof.

8. A method of treating pain, rheumatism, fever, osteoarthritis, glaucoma, or ocular hypertension, comprising administering a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof to a human in need thereof.

9. A compound of the following formula or a pharmaceutically acceptable salt thereof:

10. A compound of the following formula:

Assignees

• Japan Tobacco Inc

Inventors

• Nagamori Hironobu
• Mitani Ikuo
• Yamashita Masaki
• Hotta Takahiro
• Nakagawa Yuichi
• Ueda Masatoshi

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07D471/10

  Spiro-condensed systems · CPC title

• C07D405/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D403/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D401/12

  linked by a chain containing hetero atoms as chain links · CPC title